Actively Recruiting
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Led by University of California, Davis · Updated on 2026-02-09
56
Participants Needed
1
Research Sites
565 weeks
Total Duration
On this page
Sponsors
U
University of California, Davis
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.
CONDITIONS
Official Title
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed non-small cell lung cancer that is metastatic or unresectable (stage IIIC or IV) and suitable for standard of care immune checkpoint inhibitor-based therapy with palliative intent
- Age 18 years or older at the time of consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less (Karnofsky 50% or higher)
- Ability to understand and sign the informed consent form
- Willingness and ability to follow all study protocol requirements while enrolled
You will not qualify if you...
- Tumor with known sensitizing alterations in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1 genes
- Medical conditions preventing immune checkpoint inhibitor-based therapy as judged by the treating investigator
- Previous systemic therapy for metastatic stage IIIC or IV non-small cell lung cancer; prior systemic therapy for early or locally advanced NSCLC is allowed if completed at least 80 days before enrollment
- Any condition that the investigator believes would interfere with participant safety or study compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
Actively Recruiting
Research Team
S
Surbhi Singhal, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here